<DOC>
	<DOCNO>NCT00313781</DOCNO>
	<brief_summary>To test efficacy CP-751,871 combine docetaxel prednisone treatment prostate cancer refractory hormone therapy</brief_summary>
	<brief_title>Study CP-751,871 Combination With Docetaxel Prednisone Patients With Hormone Insensitive Prostate Cancer ( HRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis metastatic , progressive hormone refractory prostate cancer Adequate bone marrow , liver kidney function Previous treatment chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>randomize</keyword>
	<keyword>non-comparative</keyword>
	<keyword>efficacy</keyword>
</DOC>